Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.05), $0.02 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $280 thousand versus the consensus estimate of $28 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.